Cargando…

Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease

Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is currently the most common chronic liver disease and affects at least a quarter of the global adult population. It has rapidly become one of the leading causes of hepatocellular carcinoma and cirrhosis in Western countries. In this rev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Huapeng, Zhang, Xinrong, Li, Guanlin, Wong, Grace Lai-Hung, Wong, Vincent Wai-Sun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	XIA & HE Publishing Inc. 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666360/ https://www.ncbi.nlm.nih.gov/pubmed/34966660 http://dx.doi.org/10.14218/JCTH.2021.00201

Ejemplares similares

Non-invasive tests of non-alcoholic fatty liver disease
por: Li, Guanlin, et al.
Publicado: (2022)

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
por: Yip, Terry Cheuk-Fung, et al.
Publicado: (2023)

Application of transient elastography in nonalcoholic fatty liver disease
por: Zhang, Xinrong, et al.
Publicado: (2020)

U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases
por: Lin, Huapeng, et al.
Publicado: (2022)

Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory‐Wide Cohort Study
por: Zhang, Xinrong, et al.
Publicado: (2021)

Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study
por: Chiyanika, Chileka, et al.
Publicado: (2021)

Implications of comorbidities in nonalcoholic fatty liver disease
por: Song, Sherlot Juan, et al.
Publicado: (2023)

A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery
por: Liu, Shirley Yuk-Wah, et al.
Publicado: (2021)

Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease
por: Prasoppokakorn, Thaninee, et al.
Publicado: (2022)

Confounding factors of non-invasive tests for nonalcoholic fatty liver disease
por: Wai, Janae Wentong, et al.
Publicado: (2020)

Personalized management of cirrhosis by non-invasive tests of liver fibrosis
por: Wong, Grace Lai-Hung, et al.
Publicado: (2015)

High prevalence of de novo metabolic dysfunction-associated fatty liver disease after liver transplantation and the role of controlled attenuation parameter
por: Mak, Lung-Yi, et al.
Publicado: (2023)

Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease
por: Kaya, Eda, et al.
Publicado: (2022)

Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease
por: Cheng, Yu-Ming, et al.
Publicado: (2023)

Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease
por: Huang, Shang-Chin, et al.
Publicado: (2021)

Two different types of COVID-19 vaccines and serial liver biochemistries
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Mediterranean diet affects the metabolic outcome of metabolic dysfunction-associated fatty liver disease
por: Xiao, Yuji, et al.
Publicado: (2023)

Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis
por: Wong, Yu Jun, et al.
Publicado: (2023)

Diet-Quality Scores and Prevalence of Nonalcoholic Fatty Liver Disease: A Population Study Using Proton-Magnetic Resonance Spectroscopy
por: Chan, Ruth, et al.
Publicado: (2015)

Association of metformin use on metabolic acidosis in diabetic patients with chronic hepatitis B‐related cirrhosis and renal impairment
por: Yip, Terry Cheuk‐Fung, et al.
Publicado: (2021)

Three COVID-19 medications-remdesivir, molnupiravir and ritonavir-boosted nirmatrelvir-and serial liver biochemistries in 22, 456 subjects
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Minimal Risk of Drug-Induced Liver Injury With Molnupiravir and Ritonavir-Boosted Nirmatrelvir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2023)

Combination of Fibrosis-4, liver-stiffness measurement, and Fibroscan-AST score to predict liver-related outcomes in nonalcoholic fatty liver disease
por: Wong, Yu Jun, et al.
Publicado: (2023)

An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease
por: Sun, Dan-Qin, et al.
Publicado: (2023)

Higher Estimated Net Endogenous Acid Production May Be Associated with Increased Prevalence of Nonalcoholic Fatty Liver Disease in Chinese Adults in Hong Kong
por: Chan, Ruth, et al.
Publicado: (2015)

Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact
por: Yip, Terry Cheuk-Fung, et al.
Publicado: (2021)

Alanine Aminotransferase Level: The Road to Normal in 2021
por: Yip, Terry Cheuk‐Fung, et al.
Publicado: (2021)

Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
por: Han, A Lum
Publicado: (2022)

Update of liver fibrosis and steatosis with transient elastography (Fibroscan)
por: Wong, Grace Lai-Hung
Publicado: (2013)

Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy
por: Chan, Wah-Loong, et al.
Publicado: (2023)

Comparison of Outcomes Between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-alcoholic Fatty Liver Disease: A Meta-Analysis
por: Virk, Ghazala S, et al.
Publicado: (2023)

Sequential algorithm to stratify liver fibrosis risk in overweight/obese metabolic dysfunction-associated fatty liver disease
por: Lee, Chi-Ho, et al.
Publicado: (2023)

Metabolic dysfunction-associated fatty liver disease: from basic research to clinical application
por: Yang, Ruixu, et al.
Publicado: (2022)

Clinical and genetic determinants of the fatty liver–coagulation balance interplay in individuals with metabolic dysfunction
por: Valenti, Luca, et al.
Publicado: (2022)

Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment
por: Ding, Yuping, et al.
Publicado: (2023)

Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
por: Alam, Shahinul, et al.
Publicado: (2021)

Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome
por: Abenavoli, Ludovico, et al.
Publicado: (2023)

Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC
por: Liu, Lei, et al.
Publicado: (2022)

Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update
por: Alharthi, Jawaher, et al.
Publicado: (2022)

Fatty Liver Disease and Cardiovascular Risk: Impact of Metabolic Dysfunctions
por: Lee, Jung Il
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bppji9p1o48b9gp0f44io05gb9